Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NCK1 | P16333 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508363 | 0.87 | CYP1A2 (0.50) | CYP1A2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL697020 | 0.84 | DHFR (0.46) | CYP1A2ALDH1A1LMNAKDM4EGAA | |
| Hydrochloric Acid SCHEMBL509568 | 0.83 | DHFR (0.44) | CYP1A2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL509539 | 0.82 | XDH (0.50) | CYP1A2ALDH1A1KDM4ERAB9AMEN1 | |
| SCHEMBL509564 | 0.79 | ADORA2A (0.47) | CYP1A2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL10389070 | 0.78 | DHFR (0.46) | CYP1A2ALDH1A1KDM4EHPGDCYP2A6 | |
| SCHEMBL509287 | 0.76 | RAD52 (0.59) | ALDH1A1LMNAKDM4EGAARAB9A | |
| SCHEMBL510084 | 0.75 | GRM2 (0.46) | HPGDRAB9ARAD52MEN1NPC1 | |
| SCHEMBL509538 | 0.75 | SCN2A (0.48) | ALDH1A1KDM4EHPGDHSD17B10RAB9A | |
| SCHEMBL8286196 | 0.74 | ALDH1A1 (0.47) | CYP1A2ALDH1A1LMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | CYP1A2 203/4885ALDH1A1 997/4885LMNA 2593/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | CYP1A2 203/4885ALDH1A1 997/4885LMNA 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.